This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0883073808321042v1 24/1/56    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Forrester, M. B. Articles by Kornberg, A. J. Search for Related Content PubMed PubMed Citation Articles by Forrester, M. B. Articles by Kornberg, A. J. Social Bookmarking                         What's this?

Multiple Sclerosis in Childhood: Clinical and Radiological Features

¹ Department of Neurology, Royal Children’s Hospital, Melbourne, Australia
² Department of Radiology, Royal Children’s Hospital, Melbourne, and the University of Melbourne, Parkville, Australia
³ Department of Neurology, Royal Children's Hospital, University of Melbourne, Parkville, Australia

^* To whom correspondence should be addressed. E-mail: andrew.kornberg{at}rch.org.au.

	Abstract

We analyzed the medical records and cerebral imaging of 30 children with early onset multiple sclerosis to compare the clinical and neuro-radiological features with acute demyelinating encephalomyelitis and adult multiple sclerosis. The female:male ratio was 1.3 before the age of 12 years and increased to 4.3 after age 12 years. Optic neuritis and pyramidal dysfunction were the most common presenting clinical features. The most common radiological features at first imaging were periventricular (77.2%), corpus callosal demyelination (63.6%), gadolinium enhancement (62.5%), and Dawson’s fingers (40.9%). The median relapse rate per patient year was 1.2 ([IQR] 0.6-2.0). Seven patients reached a moderate Expanded-Disability-Status-Scale score of 3 and 3 patients were more severely affected (score of 6). Expanded-Disability-Status-Scale score increased by 0.7 for every relapse. Ten patients were commenced on immunomodulatory therapy (Interferon beta 1a, n = 9; Interferon beta 1b, n = 3; or Glatiramer acetate, n = 1), the majority of who had minimal side effects and a reduction in relapse rate.

First published on October 21, 2008, doi:10.1177/0883073808321042

Journal of Child Neurology 2009;24:56.

A more recent version of this article appeared on January 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?